Value Drug Company v. Amneal Pharmaceuticals, Inc.

N.D. Cal. · No. 3:26-cv-07780

No federal docket timeline hydrated for this case yet (state-court settlements have no RECAP docket).

Our records for this case (1)

Matter	Type	Practice area	Court	Date	Value
Amneal Pharmaceuticals, Inc.source ↗ filed by Berger Montague Pc · No. 3:26-cv-07780 · 15:1 Antitrust Litigation · view case timeline → Comparable settlements $3.50M–$34B ▾ No rulings exist yet for this exact theory/defendant, but comparable pharma price-fixing settlements (Teva $35M, Actelion $65M) show these cases often resolve rather than proceed to trial, suggesting plausible survival past initial motions given typical antitrust pleading standards in pharma pricing MDLs. Comparable settlements $3.50M–$34B median $65M · n=7 Visa and Mastercar $34B · RealPage $359.93M · Polyvinyl chloride $136M Comparable verdict: Chinese vitamin C ma $54.10M · Two Chinese vitamin $54.10M Class (from complaint): All persons and entities that purchased Colcrys (brand or generic) in the United States during the class period at supracompetitive prices. Key precedent: Teva $35M settlement is most analogous — same industry, single-drug supracompetitive pricing theory, similar generic/branded overlap dynamics. Main risk: Small, low-volume specialty drug (Colcrys) may yield a narrower class and lower damages than larger antitrust actions like Visa/Mastercard or RealPage. Rough EV model (wide — class size is the big unknown, not a prediction): $2.50M–$160M No rulings or defendant history exist for this theory; estimates rely on cross-industry pharma antitrust settlement analogs, not case-specific evidence. · grounded in 0 rulings, 7 settlements, 2 verdicts	Filing	Antitrust / Price-Fixing	N.D. Cal.	2026-07-27	$3.50M–$34B comparable settlements